Meticrane is a diuretic and a potent peripheral-type benzodiazepine receptor (PBR) inhibitor (IC50= 1 μM). Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension[3]. Meticrane is highly ranked in the connectivity map (cMap) analysis, and it does not have any known anti-cancer or immune-stimulating effect. Co-treatment with Meticrane significantly enhances treatment efficacy of CTLA-4 blockade[4]. In vitro assays performed in presence of 6-hydroxycoumarin and meticrane, among the highly affinity predicted binders, confirmed a dose-dependent inhibition (17-81%) of patulin production by 6-hydroxycoumarin (10 µM-1 mM concentration range), whereas the approved drug meticrane inhibited patulin production by 43% already at 10 µM. Furthermore, 6-hydroxycoumarin and meticrane caused a 60 and 41% reduction of patulin production, respectively, in vivo on apples at 100 µg/wound[5].
搜索
